OA11051A - Fused bicyclic pyrimidine derivatives - Google Patents

Fused bicyclic pyrimidine derivatives Download PDF

Info

Publication number
OA11051A
OA11051A OA9900107A OA9900107A OA11051A OA 11051 A OA11051 A OA 11051A OA 9900107 A OA9900107 A OA 9900107A OA 9900107 A OA9900107 A OA 9900107A OA 11051 A OA11051 A OA 11051A
Authority
OA
OAPI
Prior art keywords
phenyl
alkyl
compound
pyrrolo
cancer
Prior art date
Application number
OA9900107A
Other languages
English (en)
Inventor
Daniel Arnold Lee
Mikel Paul Moyer
Susan Beth Sobolov-Jaynes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11051A publication Critical patent/OA11051A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
OA9900107A 1996-11-27 1999-05-24 Fused bicyclic pyrimidine derivatives OA11051A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3186296P 1996-11-27 1996-11-27
US4184697P 1997-04-09 1997-04-09

Publications (1)

Publication Number Publication Date
OA11051A true OA11051A (en) 2003-03-07

Family

ID=26707706

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9900107A OA11051A (en) 1996-11-27 1999-05-24 Fused bicyclic pyrimidine derivatives

Country Status (24)

Country Link
US (1) US6413971B1 (fr)
EP (1) EP0946554A1 (fr)
JP (1) JP2000505109A (fr)
KR (1) KR20000057228A (fr)
CN (1) CN1237177A (fr)
AP (1) AP9701146A0 (fr)
AR (1) AR010740A1 (fr)
AU (1) AU4718997A (fr)
BG (1) BG103417A (fr)
BR (1) BR9713552A (fr)
CA (1) CA2272705C (fr)
CO (1) CO4650037A1 (fr)
HN (1) HN1997000146A (fr)
HR (1) HRP970641A2 (fr)
ID (1) ID18958A (fr)
IL (1) IL129825A0 (fr)
IS (1) IS5041A (fr)
MA (1) MA26452A1 (fr)
NO (1) NO992524D0 (fr)
OA (1) OA11051A (fr)
PA (1) PA8442001A1 (fr)
PE (1) PE17299A1 (fr)
TN (1) TNSN97192A1 (fr)
WO (1) WO1998023613A1 (fr)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT888349E (pt) * 1996-01-23 2002-10-31 Novartis Ag Pirrolopirimidinas e processos para a sua preparacao
CZ291386B6 (cs) 1996-02-13 2003-02-12 Zeneca Limited Chinazolinové deriváty jako inhibitory VEGF, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
HRP970371A2 (en) * 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
KR100567649B1 (ko) 1996-09-25 2006-04-05 아스트라제네카 유케이 리미티드 혈관 내피 성장 인자와 같은 성장 인자의 효과를 억제하는 퀴놀린 유도체
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
EP1005470B1 (fr) 1997-08-22 2007-08-01 AstraZeneca AB Derives d'oxindolylquinazoline utiles comme inhibiteurs d'angiogenese
DK1087970T3 (da) * 1998-06-19 2004-08-02 Pfizer Prod Inc Pyrrol[2,3-d]pyrimidin forbindelser
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
UA71945C2 (en) * 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
ES2234698T3 (es) 1999-10-19 2005-07-01 MERCK & CO., INC. Inhibidores de tirosina quinasa.
US6794393B1 (en) 1999-10-19 2004-09-21 Merck & Co., Inc. Tyrosine kinase inhibitors
UA72946C2 (uk) 1999-11-05 2005-05-16 Астразенека Аб Похідні хіназоліну як інгібітори васкулярного ендотеліального фактора росту (vegf)
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
US6610688B2 (en) 1999-12-21 2003-08-26 Sugen, Inc. 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
PT1287001E (pt) 2000-06-06 2004-12-31 Pfizer Prod Inc Derivados de tiofeno uteis como agentes anticancerigenos
ES2257410T3 (es) 2000-06-26 2006-08-01 Pfizer Products Inc. Compuestos de pirrolo(2,3-d)pirimidina como agentes inmunosupresores.
AU2002226877B2 (en) 2000-10-17 2006-01-12 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
KR100589032B1 (ko) 2000-10-20 2006-06-14 에자이 가부시키가이샤 질소 함유 방향환 유도체
MXPA03003612A (es) 2000-10-23 2003-06-19 Smithkline Beecham Corp Compuestos novedosos.
TWI238824B (en) 2001-05-14 2005-09-01 Novartis Ag 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives
US7301023B2 (en) 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
WO2003000194A2 (fr) 2001-06-21 2003-01-03 Pfizer Inc. Derives bicycliques de pyridine et de pyrimidine utiles en tant qu'agents anticancereux
GB0115393D0 (en) * 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
US7169788B2 (en) 2001-10-30 2007-01-30 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1471910A2 (fr) 2002-01-17 2004-11-03 Neurogen Corporation Analogues de quinazoline-4-ylamine substitues comme modulateurs de receptors de la capsaicin
AU2003206068A1 (en) 2002-03-01 2003-09-16 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
PL378246A1 (pl) 2002-11-26 2006-03-20 Pfizer Products Inc. Sposób leczenia odrzucania przeszczepu
EP1569926A1 (fr) * 2002-12-13 2005-09-07 Neurogen Corporation Utilisation d'analogues de la quinazolin-4-ylamine substitues par acide carboxylique, phosphate ou phosphonate, en tant que modulateurs des recepteurs de la capsaicine
US7329664B2 (en) * 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
BRPI0413876A (pt) 2003-08-29 2006-10-24 Pfizer tienopiridin-fenilacetamidas e seus derivados úteis como agentes antiangiogênicos
US20070105865A1 (en) * 2003-09-09 2007-05-10 Neurogen Corporation Substituted bicyclic quinazolin-4-ylamine derivatives
EP1683785B1 (fr) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Derive d'uree et son procede de production
MXPA06005578A (es) 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
CA2551508C (fr) 2003-12-23 2011-08-09 Pfizer Inc. Derives nouveaux de quinoleine
MXPA06013805A (es) 2004-05-27 2007-02-02 Pfizer Prod Inc Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
UA91508C2 (ru) * 2004-06-02 2010-08-10 Такеда Фармасьютикал Компани Лимитед Конденсированное гетероциклическое соединение
MEP8409A (en) * 2004-06-02 2011-12-20 Fused heterocyclic compound
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
GB0423554D0 (en) * 2004-10-22 2004-11-24 Cancer Rec Tech Ltd Therapeutic compounds
US7423043B2 (en) 2005-02-18 2008-09-09 Lexicon Pharmaceuticals, Inc. 4-Piperidin-1-yl-7H-pyrrolo[2,3-d]pyrimidine compounds
US7541367B2 (en) * 2005-05-31 2009-06-02 Janssen Pharmaceutica, N.V. 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders
EP2281901B1 (fr) 2005-08-02 2013-11-27 Eisai R&D Management Co., Ltd. Composition pharmaceutique anti-tumeur avec des inhibiteurs d'angiogénèse
CN102702194A (zh) 2005-12-21 2012-10-03 雅培制药有限公司 抗病毒化合物
EP1971611B1 (fr) 2005-12-21 2012-10-10 Abbott Laboratories Composes anti-viraux
EP2345652A1 (fr) 2005-12-21 2011-07-20 Abbott Laboratories Composées antivirales
TW200738707A (en) * 2005-12-21 2007-10-16 Abbott Lab Anti-viral compounds
WO2007076034A2 (fr) 2005-12-21 2007-07-05 Abbott Laboratories Composes antiviraux
US7851468B2 (en) * 2006-05-15 2010-12-14 Cephalon, Inc. Substituted pyrazolo[3,4-d]pyrimidines
CN101443009A (zh) 2006-05-18 2009-05-27 卫材R&D管理有限公司 针对甲状腺癌的抗肿瘤剂
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
BRPI0720169A2 (pt) 2006-12-12 2013-12-24 Takeda Pharmaceutical Composto ou um sal do mesmo, prodroga, agente farmacêutico, método para a profilaxia ou tratamento de câncer, e, uso do composto
CA2672737A1 (fr) 2006-12-20 2008-11-06 Abbott Laboratories Composes antiviraux
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
JP5638244B2 (ja) 2007-11-09 2014-12-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質と抗腫瘍性白金錯体との併用
ES2734288T3 (es) * 2007-11-28 2019-12-05 Dana Farber Cancer Inst Inc Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
JPWO2009113560A1 (ja) 2008-03-12 2011-07-21 武田薬品工業株式会社 縮合複素環化合物
NZ605292A (en) 2008-08-20 2014-06-27 Zoetis Services Llc Pyrrolo[2,3-d]pyrimidine compounds
WO2011018894A1 (fr) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Dérivés de pyrrolopyrimidine comme modulateurs des canaux potassium
US9012458B2 (en) 2010-06-25 2015-04-21 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
CA2826295C (fr) 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Inhibiteurs pyrimidines bicycliques et tricycliques de tyrosine kinase ayant une activite antitubuline, et methodes de traitement d'un patient
EP2700403B1 (fr) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Agent thérapeutique pour les tumeurs
WO2012166899A2 (fr) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de la thyroïde et du rein vis-à-vis de composés lenvatinib
WO2013174735A1 (fr) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Benzothienopyrimidines substituées
EP2867236B1 (fr) 2012-06-29 2017-06-14 Pfizer Inc Nouvelles 7h-pyrrolo[2,3-d]pyrimidines substituées par un groupe amino en position 4, utilisées comme inhibiteurs de lrrk2
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
CA2885783A1 (fr) 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Indazol-pyrrolopyrimidines substituees utiles dans le traitement de maladies hyperproliferatives
US20150218173A1 (en) 2012-09-26 2015-08-06 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperfoliferative disorders
EA033655B1 (ru) 2012-11-29 2019-11-13 Merck Patent Gmbh Производные азахиназолин карбоксамида
KR20150098605A (ko) 2012-12-21 2015-08-28 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 비정질 형태 및 그의 제조방법
SG11201509278XA (en) 2013-05-14 2015-12-30 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
US9695171B2 (en) 2013-12-17 2017-07-04 Pfizer Inc. 3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors
US10683293B2 (en) 2014-08-04 2020-06-16 Nuevolution A/S Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
PL3524595T3 (pl) 2014-08-28 2022-10-31 Eisai R&D Management Co., Ltd. Pochodna chinoliny o wysokiej czystości i sposób jej wytwarzania
SI3263106T1 (sl) 2015-02-25 2024-02-29 Eisai R&D Management Co., Ltd. Postopek zatiranja grenkobe derivata kinolina
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
EP3636283A1 (fr) 2015-06-04 2020-04-15 Pfizer Inc Formes galéniques solides de palbociclib
MX2017015896A (es) 2015-06-16 2018-08-09 Eisai R&D Man Co Ltd Agente anticancerigeno.
WO2017046675A1 (fr) 2015-09-14 2017-03-23 Pfizer Inc. Nouveaux dérivés imidazo [4,5-c] quinoline et imidazo [4,5-c] [1,5] naphthyridine utilisés comme inhibiteurs de lrrk2
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
SI3497103T1 (sl) 2016-08-15 2021-07-30 Pfizer Inc. Zaviralci piridopirimdiona CDK2/4/6
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor
JP2021098692A (ja) 2019-12-20 2021-07-01 ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎ Ａ／Ｓ 核内受容体に対して活性の化合物
US11780843B2 (en) 2020-03-31 2023-10-10 Nuevolution A/S Compounds active towards nuclear receptors
EP4126875A1 (fr) 2020-03-31 2023-02-08 Nuevolution A/S Composés actifs vis-à-vis des récepteurs nucléaires

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US6765008B1 (en) 1992-12-17 2004-07-20 Pfizer Inc Pyrrolopyrimidines as CRF antagonists
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
BR9506936A (pt) 1994-02-23 1997-09-09 Pfizer Derivados de quinazolina substituídos com 4-heterociclila processos para sua preparaçao e seu uso como agentes anticancerosos
DK0682027T3 (da) * 1994-05-03 1998-05-04 Ciba Geigy Ag Pyrrolopyrimidinderivater med antiproliferativ virkning
JPH089637A (ja) * 1994-06-20 1996-01-12 Shindengen Electric Mfg Co Ltd Ｆｅｔによる出力スイッチの駆動回路
ES2150113T3 (es) * 1995-04-03 2000-11-16 Novartis Ag Derivados de pirazol y procedimientos para la preparacion de los mismos.
US5644057A (en) * 1995-05-12 1997-07-01 Neurogen Corporation Deazapurine derivatives; a new class of CRF1 specific ligands
US5804685A (en) * 1995-06-07 1998-09-08 Neurogen Corporation Deazapurine derivatives: a new class of CRF1 specific ligands
JPH08329674A (ja) * 1995-06-02 1996-12-13 Hitachi Ltd 半導体装置
ES2203642T3 (es) * 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
HUP9900330A3 (en) * 1995-07-06 2001-08-28 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
WO1998023616A1 (fr) * 1996-11-26 1998-06-04 American Cyanamid Company Derives biaryl-pyridoquinazolinone comme agents anticancereux

Also Published As

Publication number Publication date
BG103417A (en) 2000-06-30
IL129825A0 (en) 2000-02-29
AR010740A1 (es) 2000-07-12
WO1998023613A1 (fr) 1998-06-04
IS5041A (is) 1999-04-30
US20020045630A1 (en) 2002-04-18
BR9713552A (pt) 2000-01-25
JP2000505109A (ja) 2000-04-25
TNSN97192A1 (fr) 2005-03-15
PA8442001A1 (es) 2000-05-24
CN1237177A (zh) 1999-12-01
CA2272705C (fr) 2003-03-18
NO992524L (no) 1999-05-26
KR20000057228A (ko) 2000-09-15
EP0946554A1 (fr) 1999-10-06
HN1997000146A (es) 1998-02-26
CO4650037A1 (es) 1998-09-03
CA2272705A1 (fr) 1998-06-04
AP9701146A0 (en) 1998-01-31
PE17299A1 (es) 1999-02-19
ID18958A (id) 1998-05-28
MA26452A1 (fr) 2004-12-20
HRP970641A2 (en) 1998-10-31
US6413971B1 (en) 2002-07-02
NO992524D0 (no) 1999-05-26
AU4718997A (en) 1998-06-22

Similar Documents

Publication Publication Date Title
OA11051A (en) Fused bicyclic pyrimidine derivatives
JP7073554B2 (ja) 肺がん、膵臓がん、または大腸がんを治療するためのＫＲＡＳ Ｇ１２Ｃ阻害剤としての、ベンズイソチアゾール、イソチアゾロ［３，４－ｂ］ピリジン、キナゾリン、フタラジン、ピリド［２，３－ｄ］ピリダジンおよびピリド［２，３－ｄ］ピリミジン誘導体
CA2223081C (fr) Derives de pyrimidine heterocycliques a noyaux condenses
US6395733B1 (en) Heterocyclic ring-fused pyrimidine derivatives
TWI650322B (zh) 嘧啶並吡咯類化合物、其製備方法、藥用組合物及其應用
JP3457164B2 (ja) アミノキナゾリン誘導体
ES2312783T3 (es) Derivados de 1h-imidazo (4,5-c)quinolina para el tratamiento de enfermedades dependientes de proteina quinasa.
US7244729B2 (en) 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives
NZ520093A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
PL201784B1 (pl) Pochodne benzimidazolu, ich zastosowanie i środek farmaceutyczny
CA2630164A1 (fr) Pyrazolo[3,4-d]pyrimidines a substitution amino en position 3 en tant qu'inhibiteurs de kinase d'epbh et de vegfr2
KR20110088960A (ko) 단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
WO2008049855A2 (fr) Nouveaux composés
TW202244049A (zh) Shp2磷酸酶抑制劑的製備及其應用
CN115677701A (zh) 一种苯并杂环化合物及其制备方法和应用
JP2021515768A (ja) オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用
WO2014113859A1 (fr) Composés 2-chloro-4-anilino-quinazoliniques inhibiteurs de protéines tyrosine kinases, compositions pharmaceutiques les comprenant, procédé pour leur production et méthode d'inhibition de tyrosine kinases
KR20200134179A (ko) N을 포함하는 헤테로아릴 유도체 및 이를 유효성분으로 포함하는 암의 예방 또는 치료용 약학적 조성물
AU2002301080B2 (en) Thienopyrimidine and Thienopyridine Derivatives Useful as Anticancer Agents
CN115433196A (zh) 一种冠醚并喹唑啉衍生物其及制备方法和应用
MXPA00004491A (en) Thienopyrimidine and thienopyridine derivatives useful as anticancer agents